CG 0070

Drug Profile

CG 0070

Alternative Names: CG0070

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cold Genesys
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer

Most Recent Events

  • 27 Jul 2016 Cold Genesys terminates the phase II/III BOND trial in Bladder cancer (Second-line therapy or greater) in USA (Intravesicular) because of change in trial design (NCT01438112)
  • 06 May 2016 Efficacy and safety data from a phase II/III trial in Bladder cancer presented at the 111th Annual Meeting of the American Urological Association (AUA - 2016)
  • 04 Jan 2016 Phase-III clinical trials in Bladder cancer (Second-line therapy or greater) in USA (Intravesicular) (NCT02365818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top